Sign up
Pharma Capital

Canopy Health teams up with Quebec consultancy firm

The group, partly-owned by Canopy Growth Corp, has entered a three-year consultancy agreement with EPIC Consulting Inc.
cannabis leaves
CHI is looking at gaps in the pharma industry which could be filled by safe cannabis-based medicines

Canopy Health Innovations, partly-owned by Canopy Growth Corporation (TSE:WEED), has brought on board a consultancy firm to help it develop and commercialise cannabis-based medicines as quickly as possible.

CHI and Quebec-based EPIC Consulting Inc. have agreed a three-year partnership during which they will work together to develop drug formulations and delivery systems targeting unmet medical needs.

EPIC is also the firm of Dr Mark Ware who has been conducting medical cannabis research for the best part of two decades and is well-respected in the field.

“We have a unique opportunity here in Canada to study cannabis and develop products that will change the world,” said Canopy Health President Marc Wayne.

“Bringing Dr Ware in at this exciting moment to consult on our clinical research strategy is an important step towards our vision of bringing validated cannabis medicines to market as quickly as possible.”

Canopy Growth Corp has first refusal to commercialise any resulting intellectual property developed by CHI.

Shares in Canopy Growth were up 1%, or C$0.10, to C$12.16.

Register here to be notified of future Company articles
View full profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.